Filtered By:
Condition: Asthma
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 147 results found since Jan 2013.
Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review
This study describes published annualized asthma exacerbation rate (AAER) reductions from RCTs in patients with allergic severe asthma, overall and by baseline BEC category. A literature search was performed to identify published phase 3 RCT data of US Food and Drug Administration-approved biologics for severe asthma in patients with severe, uncontrolled asthma and confirmed sensitization to perennial aeroallergens. Analyses focused on AAER reduction versus placebo in the overall population and/or in those with an elevated or low BEC at baseline or screening. Baseline serum total immunoglobulin E levels varied between RCT ...
Source: Adv Data - September 12, 2023 Category: Epidemiology Authors: Jonathan A Bernstein Jean-Pierre Llanos Gillian Hunter Neil Martin Christopher S Ambrose Source Type: research
Use of ICS and Fast-Acting Bronchodilators in Asthma: Past, Present, and Future
J Fam Pract. 2023 Jul;72(6 Suppl):S61-S70. doi: 10.12788/jfp.0625.ABSTRACTPrimary care practitioners (PCPs) play a key role in asthma management since most patients with asthma are treated in primary care settings. Despite continual advances in asthma care, important practice gaps remain, and the high burden of asthma exacerbations persists, with 43% of children with asthma and 41% of adults with asthma in the United States experiencing an asthma exacerbation in 2020. Uncontrolled asthma, incomplete assessment of exacerbation and asthma control history, reliance on systemic corticosteroids (SCS) or short-acting beta2-agoni...
Source: The Journal of Family Practice - August 7, 2023 Category: Practice Management Authors: Neil Skolnik Marissa Norden Njira Lugogo Wendy Wright Source Type: research
